Marksans Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The results were approved by the Board of Directors on November 4, 2026. The company reported key financial figures for both standalone and consolidated operations, providing an update on its performance and financial position for the period.
Marksans Pharma Declares Q2 FY27 Results
Marksans Pharma Limited has officially published its unaudited financial results for the second quarter and the first half of the financial year ending September 30, 2026. These results encompass both standalone and consolidated financial statements. The Board of Directors of the company reviewed and approved these financial outcomes during their meeting held on November 4, 2026.
Key Financial Highlights
The disclosed financial statements provide a comprehensive overview of Marksans Pharma’s performance, including revenue, expenses, profit before tax, and profit after tax for the respective periods. The results also detail other comprehensive income and total comprehensive income. For the quarter ended September 30, 2026, standalone revenue from operations was ₹3,138.04 million, with a profit after tax of ₹855.42 million. Consolidated revenue for the same quarter stood at ₹9,401.69 million, with a profit after tax of ₹1,435.25 million.
Consolidated Performance
On a consolidated basis, for the half year ended September 30, 2026, Marksans Pharma reported revenue from operations of ₹17,809.65 million and a profit after tax of ₹3,029.32 million. The consolidated total comprehensive income for the same half-year period was ₹3,501.48 million. The accompanying statements also provide details on assets, liabilities, equity, and cash flow movements.
Auditor’s Review
The financial results have undergone a limited review by M/s. MSKA & Associates LLP, Chartered Accountants, who have expressed an unmodified opinion on the standalone and consolidated financial results.
Source: BSE
